ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Japan’s Astellas Pharma has started construction of a $58 million fermentation unit in Toyama, in western Japan. The new unit will be able to produce multiple types of active drug ingredients for use in clinical trials and will also support the company’s process development efforts. The firm has several drug candidates at the preclinical stage that have been obtained at least partly through fermentation of natural substances. Simultaneously, Astellas says it will restructure its R&D activities and transfer drug discovery work from its fermentation research center to its pharmacology and molecular medicine labs. It plans to construct a new fermentation research building in Tsukuba by the end of 2011 and will create a bioimaging research lab, also in Tsukuba.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter